Cargando…

P1358: WILL COVID-19 PANDEMIC CHANGE MOBILIZATION STRATEGY OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA PATIENTS FOR THE BETTER?

Detalles Bibliográficos
Autores principales:	Marques, B., Roque, A., Ruzickova, L., Carda, J. P., Gomes, M., Sarmento Ribeiro, A. B., Geraldes, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431297/ http://dx.doi.org/10.1097/01.HS9.0000848296.28542.2d

Ejemplares similares

P900: SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE
por: Duarte, S., et al.
Publicado: (2022)

Metalloproteinase inhibitors as a potential therapeutic approach in multiple myeloma: a preliminary study
por: Pais, A Sofia, et al.
Publicado: (2010)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

P1358: MINING THE GENOME FOR ERYTHROID SPECIFIC ENHANCERS TO OPTIMIZE GENE THERAPY VECTORS FOR BETA-HEMOGLOBINOPATHIES
por: Paschoudi, Kiriaki, et al.
Publicado: (2023)

1358. A Real-World Study of the Burden of Illness and Treatment Patterns Among Patients with Uncomplicated Urogenital Gonorrhea in the United States
por: Preib, Madison T, et al.
Publicado: (2021)

P1680: INFLUENCE OF D-DIMERS ON THROMBOEMBOLIC RISK IN PATIENTS WITH SARS-COV-2 IN AN INTENSIVE CARE UNIT
por: Coelho, A., et al.
Publicado: (2022)

1358. Using natural language processing to optimize case ascertainment of acute otitis media in a large, state-wide pediatric practice network
por: Herigon, Joshua C, et al.
Publicado: (2020)

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY
por: Mina, R., et al.
Publicado: (2022)

P014: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
por: Sousa, Rita Costa E., et al.
Publicado: (2022)

P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose
por: Almeida, Cátia, et al.
Publicado: (2022)

1358. Establishing Genomic SARS-CoV-2 Surveillance at the National Level: Germany, 2021
por: Oh, Djin-Ye, et al.
Publicado: (2022)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

PB2153: IMPACT OF EXTRAMEDULLARY DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: MULTICENTER RETROSPECTIVE ANALYSIS
por: e Sousa, Rita Costa, et al.
Publicado: (2023)

New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients
por: Angelopoulou, Maria K., et al.
Publicado: (2014)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Mo1358: IMPACT OF SARS-COV-2 INFECTION ON RECIPIENTS OF LIVER TRANSPLANT. REPORT OF A MEXICAN COHORT.
por: Azamar-Llamas, Daniel, et al.
Publicado: (2022)

1358. Persistence of Omicron-Related Long COVID: Examining Prevalence and Impact at 12 Months Post-Acute Infection
por: Kim, Yoonjung, et al.
Publicado: (2023)

Poor Hematopoietic Stem Cell Mobilizers in Multiple Myeloma: a Single Institution Experience.
por: Ruiz-Delgado, Guillermo J., et al.
Publicado: (2010)

PB1857: NRF2 MODULATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A POSSIBLE NEW THERAPEUTIC APPROACH
por: Carda #, J. P., et al.
Publicado: (2022)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION
por: More’, Sonia, et al.
Publicado: (2023)

Insights on Multiple Myeloma Treatment Strategies
por: Mateos, María-Victoria, et al.
Publicado: (2018)

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE
por: Massarotti, L., et al.
Publicado: (2023)

1358. A Novel Rapidly Growing Mycobacteria (RGM) Species Causing Soft Tissue and Orthopedic Hardware Infection After Trauma
por: Nguyen, David C, et al.
Publicado: (2019)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
por: Hasan Bou Issa, L., et al.
Publicado: (2022)

P856: A SINGLE-CELL FUNCTIONAL PRECISION MEDICINE LANDSCAPE OF MULTIPLE MYELOMA
por: Kropivsek, K., et al.
Publicado: (2022)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

P806: IMPACT OF MARROW HEMOPHAGOCYTOSIS IN DIAGNOSTIC DEFINITION AND PROGNOSTIC SIGNIFICANCE IN ADULT POPULATION
por: Almeida, C., et al.
Publicado: (2022)

P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.
por: Innocenti, Idanna, et al.
Publicado: (2023)

LIVING WITH MULTIPLE MYELOMA: SELF-MANAGEMENT STRATEGIES
por: LeBlanc, Matthew R, et al.
Publicado: (2019)

P1716: REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS
por: Li, X., et al.
Publicado: (2022)

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
por: Figueiredo, Amarilis, et al.
Publicado: (2019)

Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments
por: Wei, Xiaolei, et al.
Publicado: (2023)

P880: OVEREXPRESSION OF PFKFB4 PROMOTES ADAPTATION TO HYPOXIC MICROENVIRONMENT IN MULTIPLE MYELOMA
por: Yang, J., et al.
Publicado: (2022)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

P1349: EFFECT OF TRANSPLANTED CD184-POSITIVE CELLS (WITH EXPRESSION CXCR4) FOR A LONG SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA – ONE CENTER PROSPECTIVE STUDY.
por: Kopinska, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1crca5k5f2enkd63r2q6f23jsg